BeiGene Market Cap 2014-2024 | ONC

BeiGene market cap history and chart from 2014 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. BeiGene market cap as of January 03, 2025 is $17.96B.
Sector Industry Market Cap Revenue
Medical MED-BIOMED/GENE $17.962B $2.459B
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
Stock Name Country Market Cap PE Ratio
Heidelberg Materials AG (HDLMY) Germany $22.212B 0.00
BrightSphere Investment Group (AAMI) United States $0.962B 11.46
Viad Corp (PRSU) United States $0.883B 39.27
Westaim (WEDXD) Canada $0.461B 12.39
Coliseum Acquisition (RAIN) United States $0.040B 0.00
ILearningEngines (AILEQ) United States $0.000B 0.00